Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Cariprazine for Mania

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have provided informed consent prior to any study specific procedures~* Patients currently meeting the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for bipolar I disorder, as confirmed by the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (SCID) manic or mixed type with or without psychotic symptoms~* Voluntarily hospitalized for current manic episode~* Patients with normal physical examination, laboratory, vital signs,and/ or electrocardiogram (ECG)~Exclusion Criteria:~* Patients with a DSM-IV-TR diagnosis of an axis I disorder other than bipolar I disorder that was the primary focus of treatment within the previous six months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Cariprazine (Type: EXPERIMENTAL): Cariprazine 3 mg - 12 mg capsules oral administration, once per day for 3 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo dose-matching cariprazine capsules oral administration, once per day for 3 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).